Format

Send to

Choose Destination
J Clin Sleep Med. 2014 Mar 15;10(3):255-62. doi: 10.5664/jcsm.3522.

Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial.

Author information

1
Department of Orthodontics, Jagiellonian University Medical College, Krakow, Poland.
2
Department of Oral Health Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
3
Department of Pulmonology, Jagiellonian University Medical College, Krakow, Poland.
4
Department of Biochemistry, University of Vermont, Burlington, VT.
5
Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

Abstract

STUDY OBJECTIVE:

Obstructive sleep apnea (OSA) is associated with systemic inflammation and a hypercoagulable state. The current study aim was to investigate whether mandibular advancement splint (MAS) therapy affects inflammatory and hemostatic parameters in patients with mild-to-moderate OSA.

METHODS:

Twenty-two patients with mild-to-moderate OSA and 16 control subjects were studied. OSA subjects were treated with a titratable MAS for 6 months. Baseline plasma C-reactive protein, interleukin-1β, interleukin-10, interleukin-6, P-selectin, fibrinogen, D-dimer, plasminogen activator inhibitor-1 (PAI-1), thrombin-antithrombin complex, activated thrombin-activatable fibrinolysis inhibitor (TAFIa), 6-keto-PGF1α, glucose, and fibrin clot lysis time (CLT) were measured in all subjects. After 3 months of MAS therapy, measurements were repeated for the 22 patients, and after 6 months all measurements were repeated for all study subjects.

RESULTS:

MAS treatment reduced significantly AHI at 3 months (24 vs 13.1/h) and further improved it at 6 months (13.1 vs 7.05/h). Compared with controls, OSA subjects had a significant higher baseline mean levels of fibrinogen, TAFIa, 6-keto-PGF1α, and glucose. MAS treatment significantly improved levels of IL-1β, D-dimer, TAFIa, and CLT. Despite residual apneas, MAS treatment group presented similar measured homeostatic and inflammatory levels to controls except for glucose.

CONCLUSION:

Treatment with MAS in mild-to-moderate OSA subjects improves the inflammatory profile and homeostatic markers.

CITATION:

Niżankowska-Jędrzejczyk A; Almeida FR; Lowe AA; Kania A; Nastałek P; Mejza F; Foley JH; Niżankowska-Mogilnicka E; Undas A. Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial.

KEYWORDS:

Obstructive sleep apnea; TAFIa; fibrinolysis; homeostatic markers; inflammatory markers; interleukin-10; mandibular advancement splint; oral appliance; sleep apnea; snoring

PMID:
24634622
PMCID:
PMC3927430
DOI:
10.5664/jcsm.3522
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Academy of Sleep Medicine Icon for PubMed Central
Loading ...
Support Center